Mar. 10, 2011Products
Approval obtained for partial change in dosage and administration of MEROPEN, a carbapenem antibiotic preparation
Dainippon Sumitomo Pharma Co., Ltd. (Headquarters: Osaka, Japan; President: Masayo Tada; hereinafter called “DSP”) announced that it has obtained approval for partial change in dosage and administration of MEROPEN®, a carbapenem antibiotic preparation, more specifically a change of the maximum daily dose from 2g to 3g for severe / refractory infections in Japan.
MEROPEN® is DSP's self-developed carbapenem antibiotic preparation for injection, which was launched in Japan in September 1995. This drug is widely used for various types of moderate to severe infectious diseases caused by gram-positive / gram-negative bacteria.
This medicine is sold by DSP and AstraZeneca, DSP's licensee, in more than 100 countries collectively in the world.
With respect to dosage and administration of an antibacterial drug for severe / refractory infections, particular attention has been paid in recent years to the importance of “optimal” administration based on PK-PD theory (*). In this connection, it has often been pointed out as a problem that approved dosage in Japan is low compared with those in many foreign countries. The approved maximum daily dose of MEROPEN® in Japan was 2g for severe / refractory infections, while as a result of acquisition of the approval of partial change in dosage and administration, an administration of 3g per day of MEROPEN® has become possible, which is expected to show promising results in clinical practices as well as significant bacteriological effects.
DSP expects to further contribute to improvement in the survival rate of various infections by providing information from the viewpoint of proper use of antibiotic preparations in terms of dosage and administration of MEROPEN® for general infections.
This is a concept to design the optimal administration of an anti-microbial agent by evaluating its efficacy and safety in connection with pharmacokinetics (PK), which shows how an anti-microbial agent concentration changes within human body, and pharmacodynamics (PD).
|[Brand Name]||MEROPEN® for Intravenous Drip Infusion Vial 0.25g
MEROPEN® for Intravenous Drip Infusion Vial 0.5g
MEROPEN® for Intravenous Drip Infusion Kit 0.5g
|[Generic Name]||Meropenem hydrate|
Meropenem-susceptible strains of Staphylococcus sp., Streptococcus sp., Streptococcus pneumoniae, Enterococcus sp., Neisseria meningitidis, Moraxella (Branhamella) catarrhalis, Escherichia coli, Citrobacter sp., Klebsiella sp., Enterobacter sp., Serratia sp., Proteus sp., Providencia sp., Haemophilus influenzae, Pseudomonas sp.,Pseudomonas aeruginosa, Burkholderia cepacia, Bacteroides sp. and Prevotella sp.
Septicemia, deep-seated skin infection, lymphangitis / lymphadenitis, secondary infection of traumatic wound, burn wound or operative wound, perianal abscess, osteomyelitis, arthritis, tonsillitis (including peritonsillar abscess), pneumonia, lung abscess, pyothorax, secondary infection in chronic respiratory disease, complicated cystitis, pyelonephritis, peritonitis, cholecystitis, cholangitis, liver abscess, intrauterine infection, uterine adnexitis, parametritis, purulent meningitis, endophthalmitis (including panophthalmitis),otitis media, sinusitis, phlegmon around the jaw, and gnathitis
2. Febrile neotropenia
|[Dosage and Administration]
(The changed portion is underlined.)
For adults, usually 0.5 to 1g (potency) of Meropenem is intravenously infused for 30 minutes or longer in two to three divided doses per day. The dosage should be adjusted according to the patient's age and symptoms and can be increased to 3g (potency) per day with a ceiling of 1g (potency) per time in patients with severe/refractory infection.
For children, usually 30 to 60mg (potency)/kg of meropenem is intravenously infused for 30 minutes or longer in three divided doses per day. The dosage should be adjusted according to the patient's age and symptoms and can be increased to 120mg (potency)/kg per day in children with severe / refractory infection. The dosage should not exceed the maximum daily dose of 3g (potency) for adults.
2. Febrile neutropenia
(Description omitted because of no change)
|[Manufacturer and Distributor]||Dainippon Sumitomo Pharma Co., Ltd.|